Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common diabetes drug help transplanted kidneys survive longer?

NCT ID NCT07555106

Disease control Sponsor: University of Guadalajara Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether dapagliflozin, a drug usually used for diabetes, can improve kidney function in people who have received a kidney from a living donor. Fifty-four adult transplant recipients will take either dapagliflozin or standard care for 12 months. Researchers will measure changes in kidney function, scarring, and overall health to see if the drug offers extra protection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dapagliflozin (a diabetes drug that may also protect the kidneys)
What this could lead to
If it works, this could point toward a way to help transplanted kidneys last longer and work better.
What could go wrong
This is a small, early-phase trial with only 54 people, so results may not apply to everyone. The drug could also increase the risk of infections or other side effects in transplant patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

54 people

The number who actually took part.

Started

Sep 2024

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* Inclusion Criteria: * Ability to provide written informed consent * Adult patients ≥18 years of age * First living-donor kidney transplant recipients * Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m² at screening * Receiving standard immunosuppressive therapy (tacrolimus, mycophenolate mofetil, and prednisone) with induction therapy (thymoglobulin or basiliximab) * Exclusion Criteria: * Type 1 diabetes mellitus * Recipients of deceased donor kidney transplant * History of any other solid organ transplant * Second kidney transplant * Severe cardiovascular disease (congestive heart failure class IV, recent myocardial infarction, unstable angina, stroke, or transient ischemic attack within 8 weeks prior to enrollment) * HbA1c \>12% in patients with diabetes mellitus * Current use of SGLT2 inhibitors at enrollment * Known hypersensitivity or intolerance to SGLT2 inhibitors * Pregnant or breastfeeding women * Hepatic impairment (AST or ALT \>3 times the upper limit of normal, or total bilirubin \>2 times the upper limit of normal at enrollment) * Antibody-mediated rejection (AMR) or Banff grade ≥2A acute cellular rejection during the first week post-transplant * Use of anticoagulants, nonsteroidal anti-inflammatory drugs, pentoxifylline, or mineralocorticoid receptor antagonists (spironolactone, eplerenone, finerenone) * Highly sensitized recipients or presence of donor-specific antibodies prior to enrollment * Urological disorders (including recurrent urinary tract infections or urolithiasis within 12 months prior to enrollment) or severe genital infections * Presence of de novo or recurrent glomerulopathy or BK virus nephropathy during the first week post-transplant.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Kidney transplant are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Kidney transplant Kidney transplant failure

Contacts and locations

Locations

  • Universidad de Guadalajara

    Guadalajara, Jalisco, 44250, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.